#Hoth Therapeutics #GDNF #Obesity Therapy

Hoth Therapeutics Launches a Pioneering Study on GDNF for Weight Loss

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to creating groundbreaking therapies for various illnesses, is on the verge of a significant breakthrough. They have recently announced the initiation of a U.S. Department of Veterans Affairs (VA)-backed study that aims to evaluate the efficacy of glial cell line–derived neurotrophic factor (GDNF) as a potential treatment for obesity and fatty liver disease, also known as hepatic steatosis.

Objectives of the Study

The primary objective of this study, under the capable leadership of Dr. Srinivasan at the Atlanta VA Medical Center, is to analyze GDNF’s capabilities in promoting weight loss and addressing the complications associated with fatty liver disease. Dr. Srinivasan and her research team will delve into the metabolic and neurotrophic mechanisms by which GDNF may induce these positive health outcomes.

Robb Knie, CEO of Hoth Therapeutics, expressed enthusiasm about this partnership and emphasized the ongoing global challenge obesity represents. He stated, “By targeting both neural and metabolic pathways, GDNF could signify a novel class of biologic therapy for obesity and related liver conditions.